PDF(Pubmed)
Abstract：
In this literature review, we will evaluate the effectiveness of OnabotulinumtoxinA (Botox) and anti-calcitonin gene-related peptide (anti-CGRP) in the treatment of migraine headaches. Both therapies are frequently prescribed for managing and preventing migraines and have received Food and Drug Administration (FDA) approval. The mechanism of action, side effects, compliance, cost-effectiveness, and migraine treatment provided by these two medicines were compared in the analysis of several studies. Many studies found that as Botox was administered by a doctor every three months and had fewer side effects than anti-CGRP, which is self-administered every month, it was more compliant than anti-CGRP. After examining the data, Botox is believed to be the most effective therapy. Although both therapies are efficient, this article compares them to determine which is the best management strategy.
摘要：
在这篇文献综述中，我们将评估OnabotulinumtoxinA（Botox）和抗降钙素基因相关肽（anti-CGRP）治疗偏头痛的有效性。这两种疗法通常用于管理和预防偏头痛，并已获得食品和药物管理局（FDA）的批准。作用机制,副作用,合规,成本效益，和这两种药物提供的偏头痛治疗在几个研究的分析中进行了比较。许多研究发现，由于医生每三个月服用一次肉毒杆菌素，副作用比抗CGRP少，每月自我管理，它比反CGRP更合规。检查数据后，肉毒杆菌被认为是最有效的治疗方法。虽然两种疗法都是有效的，本文对它们进行了比较，以确定哪一种是最佳的管理策略。
